Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.

Abstract

Interferon alfa-2a had minimal antitumor activity in patients with advanced renal cell carcinoma and long-term survival was achieved in a small proportion of patients. The need for continued investigation and the identification of more effective therapy for advanced renal cell carcinoma is evident from the poor overall survival rate observed in these 159 patients. The investigation of new agents and of interferon alfa-2a in combination with other agents remains a priority.

In vivo assessment of the antiproliferative properties of interferon-alpha during immunotherapy: Ki-67 (MIB-1) in patients with metastatic renal cell carcinoma

“…Patients with untreated mRCC have a poor prognosis with a median survival of only 8 months (Haas et al, 1993). However, interleukin-2 (IL-2)-and interferon-a (IFNa)-based immunotherapy can induce durable tumour regression in 5 -10% of patients with mRCC (Minasian et al, 1993;Rosenberg, 2001).…”

A feasibility study of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma

“…with 45% of the patients stopping therapy because of toxicity as a primary (ten patients) or contributing reason (four clinician/patient request). This is much higher than the 6% withdrawal rate for toxicity reported with a-interferon alone at doses greater than 9 MU three times weekly (Minasian et al 1993). The similar adverse event profile of Linomide and a-interferon (fever.…”

“…A feasibility study of roquinimex (Linomide) (Horoszewxicz et al 1989: Minasian et al 1993. with a median response duration of 12.2 months (Minasian et al 1993).…”

“…with a median response duration of 12.2 months (Minasian et al 1993). In a review of recombinant a-interferon for metastatic melanoma.…”

Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival

“…Manipulating the immune system by interleukin-2 (IL-2) based immunotherapy may induce durable tumour regression in metastatic renal cell carcinoma (mRCC) (Minasian et al, 1993;Fyfe et al, 1995;Jeal and Goa, 1997;Bordin et al, 2000;Fisher et al, 2000;Negrier et al, 2000). However, only a minority of patients benefit from treatment and consequently, many efforts have been made to assess parameters, which may predict objective response and survival in order to select those patients who most likely will benefit from treatment.…”